Nuovi Approcci alla Ferrochelazione
|
|
- Asher Smith
- 6 years ago
- Views:
Transcription
1 Il Deficit di PKD 1 patient day Nuovi Approcci alla rrochelazione M. Domenica Cappellini Fondazione Ca Granda Policlinico Università di Milano Milano May
2 Genetic and acquired iron overload Genetic iron overload Not associated with anaemia haemochromatosis type1 (HFE) haemochromatosis type 2 or juvenile (HAMP, HJV) haemochromatosis type 3 (TFR2) haemochromatosis type 4 (FPN) Associated with anaemia atransferrinaemia DMT1 deficiency aceruloplasminaemia Acquired iron overload Chronic blood transfusions Iron-loading anaemias (congenital) β-thalassaemia intermedia CDA, sideroblastic anaemia haemolytic anaemias (SCD, PKU, spherocytosis) Iron-loading anaemias (acquired) MDS (RARS) Inappropriate parenteral iron therapy CDA = congenital dyserythropoietic anaemia; PKU = phenylketonuria; RARS = refractory anaemia with ringed sideroblasts; SCD = sickle cell disease. Pietrangelo A. Hepatology. 2007;46:
3 Normal iron distribution and storage Utilization Duodenum (average, 1 2 mg per day) Dietary iron Utilization Muscle (myoglobin) (300 mg) Transferrin Storage iron Functional iron pool Transferrin Circulating erythrocytes (hemoglobin) (1800 mg) Bone marrow (300 mg) Liver (1000 mg) Sloughed mucosal cells Desquamation/menstruation Other blood loss (average, 1 2 mg per day) Iron loss Andrews NC. N Engl J Med 1999;341: , Massachusetts Medical Society, with permission Reticuloendothelial macrophages (600 mg)
4 Iron overload in different anemias Mechanisms: Transfusion Increased absorption Inappropriate parenteral therapy There is no physiologic process for excreting excess iron Increased iron intake = iron overload
5 Transfusion therapy results in iron overload Transfusions 2 units/month 24 units/year ~ 100 units/4 years: 20 g iron mg iron Body iron storage normal: 3 4 g hereditary haemochromatosis: g ~ 90% of all MDS patients become transfusiondependent
6 Iron disequilibrium in trasfused patients Transfusions GI system Liver Blood (RBC + transferrin + NTBI) RE system Heart Endocrine organs NTBI, non-transferrin-bound iron; RE, reticuloendothelial Taher A, et al. Br J Haematol 2009;147:
7 Iron disequilibrium in Iron Loading Anemias GI system Liver Blood (RBC + transferrin + NTBI) RE system Heart Endocrine organs RE, reticuloendothelial Taher A, et al. Br J Haematol 2009;147:
8 Transferrin saturation % Iron overload and organ loading Transferrin saturation due to Frequent blood transfusions, or Ineffective erythropoiesis leading to increased iron absorption Subsequent formation of NTBI in plasma Uncontrolled iron loading of organs Pituitary 100% Normal: no NTBI produced Iron overload Parathyroid Thyroid Heart Liver Pancreas Gonads 30% NTBI = non-transferrin-bound iron.
9 Organ systems affected by iron overload Organ 1,2 Pituitary Thyroid Parathyroid Heart Liver Pancreas Gonads Bones Consequences Hypogonadotropic Hypogonadism Hypothyroidism Hypoparathyroidism Cardiomyopathy Cirrhosis, carcinoma Diabetes Hypogonadotropic Hypogonadism Osteomalacia Osteoporosis These tissues share L-type calcium-dependent channels for NTBI uptake 3 1. Taher A et al. Semin Hematol 2007;44:S2 S6. Review. 2. Ebrahimpour L et al. Hematology 2012;17: Prospective cross-sectional study; n= Oudit GY et al. Nat Med 2003;9: Animal study.
10 What is chelation therapy? Iron chelators reduce body iron by complexing and enabling excretion of free iron Chelator Metal Metal Excretion Cabantchik ZI et al. Best Pract Res Clin Haematol 2005;18: Review.
11 Evolution of iron chelators 1960s DFO came into clinical use 2006 DFX approved by EMEA 2012 FBS0701 Phase II results s to 1980s s 2000s 2010s Subcutaneous DFO 1999 DFP approved by EMEA 2005 DFX approved by FDA 2011 DFP approved by FDA DFO, deferoxamine; DFP, deferiprone; DFX, deferasirox; EMEA, European Medicines Agency; FDA, US Food and Drug Administration 1. Neufeld EJ et al. Blood 2012;119: Multicenter, openlabel, randomized, Phase II study; n=73.
12 Chelators and coordination with iron DFO Hexadentate (1:1) High MW DFX Tridentate (2:1) Low MW DFP Bidentate (3:1) Low MW OH 2 N COO - N H 2 N-(H 2 C) 5 N O H 2 O H 2 O NH F e O OH 2 OH 2 HN OH 2 N O H 2 O H 2 O N N OH 2 F e OHO 2 OH 2 OH 2 N H 2 O H 2 O OH 2 F e OH 2 OH 2 OHO 2 N N N - OOC MW, molecular weight Nick H et al. Curr Med Chem 2003;102: Review.
13 Overview of iron chelators: licensed indications and contraindications Property DFO 1 DFP 2 DFX 3 Therapeutic indications Chronic iron overload due to transfusional hemosiderosis (eg in patients with TM) or primary or secondary hemochromatosis in patients who can not undergo phlebotomy (eg because of severe anemia, hypoproteinemia, or renal or cardiac failure) Iron overload in patients with TM when DFO therapy is contraindicated or inadequate Chronic iron overload due to blood transfusions in patients aged 2 years; chronic iron overload in patients aged 10 years with NTDT and with a LIC of 5 mg /g dw and a serum ferritin >300 ng/ml Contraindications Hypersensitivity to DFO; patients with severe renal disease or anuria Hypersensitivity to DFP or excipients; Henoch Schonlein purpura, urticaria and periorbital edema with skin rash have been reported Hypersensitivity to DFX or excipients; serum creatinine >2 ULN or creatinine clearance <40 ml/min; poor performance status; high-risk MDS, advanced malignancies; platelet counts < /L Please refer to prescribing information in your country of practice. liver iron concentration; MDS, myelodysplastic syndromes; NTDT, non-transfusion-dependent thalassemia; TM, thalassemia major; ULN, upper limit of normal 1. Desferal (deferoxamine) US Prescribing Information. 2011; 2. rriprox (deferiprone) US Prescribing Information. 2012; 3. EXJADE (deferasirox) US Prescribing Information
14 Overview of iron chelators: pharmacokinetic profiles Property DFO 1 DFP 2 DFX 3 Daily dose mg/kg mg/kg mg/kg Administration Half-life SC (also IV, IM); 8 12 hours, 5 7 days/week First phase: 1 hour Second phase: 6 hours Oral; TID Oral; QD 2 3 hours 8 16 hours Lipid solubility 4 Low Intermediate High Excretion Urinary, fecal Urinary cal Efficiency 10 17% efficient when given at mg/kg over 8 10 hours, 5 7 days/week 4 4% of administered dose eliminated in urine bound to iron at 25 mg/kg/day, TID 5 27% of drug eliminated in iron-bound form when given at mg/kg/day, QD 4 Please refer to prescribing information in your country of practice. IM, intramuscular; IV, intravenous; QD, once daily; SC, subcutaneous; TID, three times daily 1. Desferal (deferoxamine) US Prescribing Information. 2011; 2. rriprox (deferiprone ) US Prescribing Information. 2012; 3. EXJADE (deferasirox) US Prescribing Information. 2013; 4. Porter J et al. Blood 2005;106(11):abst 2690; 5. Hoffbrand AV et al. Blood 2003;102:17 24.
15 Iron-bound DFO is excreted in urine and feces Bile Plasma Storage Macrophage Hepatocyte Kidney ces Urine Cohen AR and Porter JB. In: Steinberg MH, et al. editors. Disorders of hemoglobin: genetics, pathophysiology, and clinical management. Cambridge: Cambridge University Press; 2001.
16 Iron-bound DFP is excreted exclusively in urine Bile Plasma Storage Macrophage Hepatocyte Kidney ces Urine Cohen AR and Porter JB. In: Steinberg MH, et al. editors. Disorders of hemoglobin: genetics, pathophysiology, and clinical management. Cambridge: Cambridge University Press; 2001.
17 Iron-bound DFX is excreted primarily in feces Bile Plasma Storage Macrophage Hepatocyte ces Kidney Urine Cohen AR and Porter JB. In: Steinberg MH, et al. editors. Disorders of hemoglobin: genetics, pathophysiology, and clinical management. Cambridge: Cambridge University Press; 2001.
18 Rare transfusion-dependent anemias Not hemoglobinopathies or MDS Production anemias Pure red cell aplasia Fanconi anemia Diamond-Blackfan anemia (DBA) Acquired aplastic anemia Myelofibrosis Hemolytic anemias Pyruvate kinase deficiency (PKD) Erythropoietic protoporphyria Chronic autoimmune hemolytic anemia Dyserythropoietic anemias Congenital dyserythropoietic anemia (CDA) types I and II
19 Cardiac iron load in different transfusion-dependent anaemias UCLH patients with cardiac MRI SCD MDS DBA PK deficiency Congenital sideroblastic TI TM Patients (%) with T2* < 20 ms MRI = magnetic resonance imaging; PK = pyruvate kinase; UCLH = University College London Hospital. Porter JB. Am J Hematol. 2007;82:
20 Pyruvate kinase deficiency (PKD) and iron overload Serum ferritin > ULN in 60% non-transfused patients Liver fibrosis and siderosis in 8/9 Cirrhosis in 2 who died age 39 and 42 years Serum ferritin is independent of age, gender, haemolysis Splenectomy is a risk factor for iron overload HLA-A3-positive patients had higher iron overload than non-hla-a3 patients ULN = Upper limit of normal. Zanella A, et al. Br J Haematol. 1993;83:
21 Iron overload in DBA Retrospective study of 31 transfusion-dependent DBA patients 54% had severe liver iron overload (LIC >15 mg /g dw) Mean LIC: 13.4 ± 6.8 mg /g dw (range ) 23% had 1 iron-related complications Hypothyroidism (4) Hypogonadism (4) Hypoparathyroidism (1) Diabetes mellitus (2) Heart disease (2) Roggero S, et al. Am J Hematol 2009;84:
22 Iron overload in CDA types I and II CDA type I CDA type II (HEMPAS) Transfusion dependent Serum ferritin Complications Usually not after age 4 months 500 1,500 ng/ml by adult age (increased absorption) Hyperbilirubinemia and gallstones Splenomegaly (80 90%) 10% 40% >1,000 ng/ml by age 50 Hyperbilirubinemia and gallstones especially with Gilberts co-inheritance Paravertebral tumours rarely Liver cirrhosis (20%) 22
23 Iron status in adults with CDA type I Case Age (years) Group A (Hb < 10 g/dl) Serum (mmol/l) TIBC (mmol/l) Transferrin saturation (%) rritin (mg/l) NTBI (mmol/l) H63D mutation Neg 2* , Neg 3* , Neg Group B (Hb > 10 g/dl) Neg 5* Neg 6* Neg Homozygous *Cases 2, 3, 5, and 6 were previously treated with deferoxamine or deferoxamine plus venesections for 1, 0.7, 3, and 9 years, respectively. All cases were C282Y mutation negative. Wickramasinghe SN, et al. Br J Haematol 1999;107:
24 Iron overload in aplastic anemia Blood transfusions are the main supportive therapy in patients with AA 1 Iron overload secondary to blood transfusion therapy in 292 patients with various types of anemia, including 90 patients with AA, has been shown to correlate with 2 increased cardiac dysfunction increased hepatic dysfunction increased death To prevent these sequelae, regularly transfused patients require iron chelation therapy 3 iron chelation therapy should be considered when serum ferritin is >1,000 ng/ml 4 AA, aplastic anemia 1. Marsh JC, et al. Br J Haematol. 2003;123: Takatoku M, et al. Eur J Haematol. 2007;78: Kushner JP, et al. Hematology ASH Educ Program. 2001: Marsh JC, et al. Br J Haematol. 2009;147:43 70.
25 EPIC: response to chelation in patients with rare transfusion-dependent anaemias 57 patients with RTDAs 34 production anaemias pure red cell aplasia (n = 20) DBA (n = 14) 23 haemolytic anaemias haemolytic anaemia of uncharacterized cause (n = 11) pyruvate kinase deficiency anaemia (n = 5) autoimmune haemolytic anaemia (n = 4) congenital erythropoietic protoporphyria (n = 2) hereditary haemolytic anaemia (n = 1) RTDA = rare transfusion-dependent anaemia. Porter JB, et al. Eur J Haematol. 2011;87:
26 Iron measures in production and haemolytic anaemias Production anaemias (n = 34) Haemolytic anaemias (n = 23) All patients (N = 57) Mean ± SD iron intake rate, mg/kg/day 0.34 ± 0.14 (n = 30) 0.33 ± 0.24 (n = 20) 0.33 ± 0.18 (n = 50) Median baseline serum ferritin (range), µg/l 2,926 (908 10,861) (n = 33) 2,682 (568 13,078) (n = 22) 2,916 (568 13,078) (n = 56) Porter JB, et al. Eur J Haematol. 2011;87:
27 Median serum ferritin (µg/l) SF levels after deferasirox therapy in production and haemolytic anaemias 6,500 5,500 4,500 3,500 2,500 1, Haemolytic anaemias Production anaemias Mean deferasirox dose Mean deferasirox dose (mg/kg/day) 500 Baseline Time (months) PDA, n: HA, n: All patients, n: Porter JB, et al. Eur J Haematol. 2011;87:
28 Summary Acquired iron overload can occur through transfusions, increased absorption or inappropriate parenteral iron Iron overload leads to development of toxic iron species, which cause tissue damage Iron overload is associated with complications such as cardiac failure, endocrinopathies and liver dysfunction Different anemias have different tissue iron distribution 29
Iron Overload Disorders and Iron Chelation Therapy
Iron Overload Disorders and Iron Chelation Therapy T. Lodewyck BHS seminar November 2014 Outline Iron overload (IO) disorders Mechanisms and pathophysiology of IO Clinical impact of IO Assessment of IO
More informationClinical Guidelines on the Use of Iron Chelation in Children Receiving Regular Blood Transfusions
Clinical Guidelines on the Use of Iron Chelation in Children Receiving Regular Blood Transfusions Version: 1 Date: 4 th May 2010 Authors: Responsible committee or Director: Review date: Target audience:
More informationIron Overload in Sickle Cell Disease Review of Cause and Treatment
Iron Overload in Sickle Cell Disease Review of Cause and Treatment Susan M. Carson RN, MSN, CPNP Nurse Practitioner III Hematology Program Children s Hospital Los Angeles Objectives Describe the effect
More informationPart I. Pathophysiology and management of Thalassemia Intermedia. M. Domenica Cappellini Fondazione IRCCS Policlinico University of Milan
Pathophysiology and management of Thalassemia Intermedia M. Domenica Cappellini Fondazione IRCCS Policlinico University of Milan 4th European Symposium on Rare Anaemias 3rd Bulgarian Symposium on Thalassaemia
More informationDEFERASIROX IN THE TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN THALASSAEMIA MAJOR AND OTHER ANAEMIAS (April 2011)
DEFERASIROX IN THE TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN THALASSAEMIA MAJOR AND OTHER ANAEMIAS (April 2011) Version: Ratified by (name of Committee): Date ratified: Date issued: Expiry date: (Document
More informationHereditary Haemochromatosis (A pint too many: discussing haemochromatosis) John Lee
Hereditary Haemochromatosis (A pint too many: discussing haemochromatosis) John Lee Hereditary Haemochromatosis A disorder of iron metabolism Inherited disorder Iron Essential micro-nutrient Toxicity when
More informationBeta-thalassemia:clinical findings,molecular defects and genotype/phenotype relationships
Beta-thalassemia:clinical findings,molecular defects and genotype/phenotype relationships Maria Domenica Cappellini Fondazione Ca Granda Policlinico IRCCS University of Milan Disclosure Member of Advisory
More informationLa Terapia della Talassemia
S.I.E. Corso nazionale di aggiornamento in ematologia clinica La Terapia della Talassemia Renzo Galanello 15/06/2007 1 Clinica Pediatrica 2-Ospedale Regionale Microcitemie.ASL8 Clinical characteristics
More informationIron Chelator Drug Class Monograph
Iron Chelator Drug Class Monograph Line of Business: Medi-Cal Effective Date: May 17, 2017 Revision Date: May 17, 2017 This policy has been developed through review of medical literature, consideration
More informationClass Update: Iron Chelators. Month/Year of Review: June 2015 Date of Last Review: June 2012
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationConsensus view on choice or iron chelation therapy in transfusional iron overload for inherited anaemias
Consensus view on choice or iron chelation therapy in transfusional iron overload for inherited anaemias The goal of iron chelation therapy in multiply transfused patients is to prevent morbidity and early
More informationStandards of Care in Thalassemia. What is Thalassemia?
Standards of Care in Thalassemia Thalassemia Support group Thomas D Coates, MD Childrens Hospital Los Angeles What is Thalassemia? Thalassemia is an inherited disorder due to a DNA mutation that causes
More informationDeferasirox in Indian children with thalassemia major: 3 years experience
[Downloaded free from http://www.ijmpo.org on Friday, June 14, 2013, IP: 109.112.89.28] Click here to download free Android application for this journa ORIGINAL ARTICLE Deferasirox in Indian children with
More informationRisks and Benefits of Blood Transfusions. Objectives. Red Cells (Erythrocytes) Understand the following:
Risks and Benefits of Blood Transfusions Patient and Family Conference Aplastic Anemia & MDS International Foundation July 10-12 th, 2009 Indianapolis, Indiana Susan M. Carson RN, MSN, CPNP Childrens Hospital
More informationISSN Asian Journal of Medical and Pharmaceutical Researches Asian J. Med. Pharm. Res. 3(3): 93-97, 2013
\\\\ 2013, Scienceline Publication www.science-line.com ISSN 2322-4789 Asian Journal of Medical and Pharmaceutical Researches Asian J. Med. Pharm. Res. 3(3): 93-97, 2013 AJMPR Comparison of Therapeutic
More informationMultidisciplinary care. Michael Angastiniotis
Multidisciplinary care Michael Angastiniotis Pathopysiology of β-thalassaemia Thalassaemia syndromes are inherited haemoglobin disorders caused by defective and imbalanced globin production Excess free
More informationHow far one should go with iron chelation in thalassemia? Is iron deficiency indicated?
How far one should go with iron chelation in thalassemia? Is iron deficiency indicated? DR. KALLISTHENI FARMAKI THALASSAEMIA UNIT GENERAL HOSPITAL OF CORINTH, GREECE VASILI BERDOUKAS PEDIATRIC HEMATOLOGIST
More informationEffects of monotherapy and combined therapy on LPI
Effects of monotherapy and combined therapy on LPI 14 12 DFO 40 mg/kg/day 14 12 Deferiprone 75 mg/kg/day 14 12 Deferiprone 75 mg/kg/day DFO 40 mg/kg/day DFO 40 mg/kg/day LPI (μm) 10 8 6 LPI (μm) 10 8 6
More informationOverview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload
Int J Hematol (2008) 88:24 29 DOI 10.1007/s12185-008-0118-z PROGRESS IN HEMATOLOGY Transfusional iron overload and iron chelation therapy Overview of guidelines on iron chelation therapy in patients with
More informationA group of inherited disorders characterized by reduced or absent amounts of hemoglobin, the oxygencarrying protein inside the red blood cells.
Thalassemia A group of inherited disorders characterized by reduced or absent amounts of hemoglobin, the oxygencarrying protein inside the red blood cells. Types of Thallasemia 1) Thalassemia trait 2)
More informationHemosiderin. Livia Vida 2018
Hemosiderin Livia Vida 2018 Questions Histochemical caracteristics of the different pigments. Exogenous pigments. Hemoglobinogenic pigments. Causes and forms of jaundice. Hemoglobinogenic pigments. Pathological
More informationThe problem with pumping too much iron
The problem with pumping too much iron Stephen D. Zucker, M.D. Professor of Medicine Director of Hepatology Disclosures NONE* * Would be pleased to entertain any reasonable offer Brief History of Hemochromatosis
More informationReal-World Use of Iron Chelators
STRATEGIES FOR OPTIMAL MANAGEMENT OF THALASSEMIA NOW AND IN THE FUTURE Real-World Use of Iron Chelators Janet L. Kwiatkowski 1 1 Children s Hospital of Philadelphia and University of Pennsylvania School
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Exjade, Jadenu) Reference Number: CP.PHAR.145 Effective Date: 11.01.15 Last Review Date: 08.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end
More informationBaseline investigations prior to starting chelation therapy include: Serum ferritin, transferrin saturation, creatinine and liver enzymes.
14. IRON OVERLOAD Principles To prevent transfusional iron overload in SCD. To diagnose and monitor transfusional iron overload. To initiate the appropriate iron chelation therapy at the appropriate time.
More informationHereditary Hemochromatosis: What Have We Learnt from Population Studies Professor John K. Olynyk
Hereditary Hemochromatosis: What Have We Learnt from Population Studies School of Medicine & Pharmacology University of Western Australia & Department of Gastroenterology Fremantle Hospital 1 The amount
More informationMetabolic Liver Diseases
Metabolic Liver Diseases Howard J. Worman, M. D. Department of Medicine Columbia University College of Physicians and Surgeons Three Classical Inherited Disorders of Metabolism Affecting the Liver Hereditary
More informationHormone related problems (Endocrinopathies and osteoporosis) Vincenzo de Sanctis Ferrara.
Hormone related problems (Endocrinopathies and osteoporosis) Vincenzo de Sanctis Ferrara vdesanctis@libero.it 6 th EUROPEAN SYMPOSIUM ON RARE ANAEMIAS 1 st Dutch-Belgian meeting for patients and health
More informationCorporate Medical Policy
Corporate Medical Policy Chelation Therapy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: chelation_therapy 12/1995 2/2018 2/2019 2/2018 Description of Procedure or Service Chelation
More informationHematopoiesis, The hematopoietic machinery requires a constant supply iron, vitamin B 12, and folic acid.
Hematopoiesis, 200 billion new blood cells per day The hematopoietic machinery requires a constant supply iron, vitamin B 12, and folic acid. hematopoietic growth factors, proteins that regulate the proliferation
More informationManagement of anemia in CKD
Management of anemia in CKD Pierre Cochat, MD PhD Professor of Pediatrics Chair, Pediatrics & Pediatric Surgery Department Head, Center for Rare Renal Diseases Néphrogones Hospices Civils de Lyon & University
More informationMicrocytic Hypochromic Anemia An Approach to Diagnosis
Microcytic Hypochromic Anemia An Approach to Diagnosis Decreased hemoglobin synthesis gives rise to microcytic hypochromic anemias. Hypochromic anemias are characterized by normal cellular proliferation
More informationStudy on Safety and Efficacy of Deferasirox in the treatment of Thalassemia in a South Indian Tertiary Care Hospital
Research Article Study on Safety and Efficacy of Deferasirox in the treatment of Thalassemia in a South Indian Tertiary Care Hospital Siva Shankar Reddy Y *1, Umesh Kamrthi 2 and Balasubramanian Kumar
More informationDrugs Used in Anemia
Drugs Used in Anemia Drugs of Anemia Anemia is defined as a below-normal plasma hemoglobin concentration resulting from: a decreased number of circulating red blood cells or an abnormally low total hemoglobin
More informationDaily alternating deferasirox and deferiprone therapy for hard-to-chelate β-thalassemia major patients
Daily alternating deferasirox and deferiprone therapy for hard-to-chelate β-thalassemia major patients Manuela Balocco, Paola Carrara, Valeria Pinto, Gian Luca Forni To cite this version: Manuela Balocco,
More informationExjade (tablets for oral suspension), Jadenu (deferasirox)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.99.02 Subject: Exjade Jadenu Page: 1 of 5 Last Review Date: December 2, 2016 Exjade Jadenu Description
More informationC-LICNET NETWORK: POTENTIAL WORLDWIDE MRI NETWORK FOR THE MANAGEMENT OF THALASSEMIA SYNDROMES
C-LICNET NETWORK: POTENTIAL WORLDWIDE MRI NETWORK FOR THE MANAGEMENT OF THALASSEMIA SYNDROMES Prof. Aurelio Maggio Campus of Hematology Franco and Piera Cutino A.O. Riuniti Villa Sofia Cervello - Palermo
More informationEvidence for the Safety of Fortifying Flour with Iron in the Presence of Thalassemia and Other Blood Disorders
Evidence for the Safety of Fortifying Flour with Iron in the Presence of Thalassemia and Other Blood Disorders Althea M Grant, PhD Chief, Epidemiology and Surveillance Branch, Division of Blood Disorders,
More informationKELFER Capsules (Deferiprone)
Published on: 22 Sep 2014 KELFER Capsules (Deferiprone) Composition KELFER-250 Capsules Each capsule contains Deferiprone 250 mg KELFER-500 Capsules Each capsule contains Deferiprone 500 mg Dosage Form
More informationRegular teaching provided in ED, Paediatric Specialist Trainees Regional Training days and nursing training programmes.
Iron chelation in Children with Haemoglobinopathy Trust Ref: C19/2016 1. Introduction The goal of iron chelation therapy in multiply transfused patients is to prevent morbidity and early mortality from
More informationNURSING CONSIDERATIONS IN THE MANAGEMENT OF PATIENTS WITH CHRONIC TRANSFUSIONAL IRON OVERLOAD
A supplement to oncology nurse advisor May 2010 OncologyNurseAdvisor www.oncologynurseadvisor.com NURSING CONSIDERATIONS IN THE MANAGEMENT OF PATIENTS WITH CHRONIC TRANSFUSIONAL IRON OVERLOAD INTRODUCTION
More informationDrug Review. Deferasirox: The New Oral Iron Chelator
Drug Review Deferasirox: The New Oral Iron Chelator A.P. Dubey S. Sudha Ankit Parakh Deferasirox is a new tridentate oral iron chelator developed by computer remodeling recently approved by FDA for children
More informationANEMIA & HEMODIALYSIS
ANEMIA & HEMODIALYSIS The anemia of CKD is, in most patients, normocytic and normochromic, and is due primarily to reduced production of erythropoietin by the kidney and to shortened red cell survival.
More informationLabile Plasma Iron: The Need and the Answer
Labile Plasma Iron: The Need and the Answer Z. Ioav Cabantchik and William Breuer Department of Biological Chemistry, The Hebrew University of Jerusalem, 91904 Jerusalem, Israel Chronic diseases of iron
More informationExjade. Exjade (deferasirox) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.11.02 Subject: Exjade Page: 1 of 5 Last Review Date: December 5, 2014 Exjade Description Exjade (deferasirox)
More informationKELFER Deferiprone. COMPOSITION KELFER-250 Capsules Each capsule contains Deferiprone 250 mg
KELFER Deferiprone COMPOSITION KELFER-250 Capsules Each capsule contains Deferiprone 250 mg KELFER-500 Capsules Each capsule contains Deferiprone 500 mg DOSAGE FORM Capsules PHARMACOLOGY Pharmacodynamics
More informationJMSCR Vol 06 Issue 08 Page August 2018
www.jmscr.igmpublication.org Impact Factor (SJIF): 6.379 Index Copernicus Value: 71.58 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v6i8.08 A study on safety and efficacy
More informationSurvival and Disease Complication of Thalassemia Major: Experience of 14 Years at King Abdulaziz University Hospital, Jeddah, KSA
JKAU: Med. Sci., Vol. 17 No. 1, pp: 19-28 (2010 A.D. / 1431 A.H.) DOI: 10.4197/Med. 17-1.3 Survival and Disease Complication of Thalassemia Major: Experience of 14 Years at King Abdulaziz University Hospital,
More informationHereditary Haemochromatosis For GPs
Hereditary Haemochromatosis For GPs What is Hereditary Haemochromatosis? Hereditary Haemochromatosis () is a common autosomal recessive disease resulting in excessive absorption of dietary iron from the
More informationMetabolic Liver Disease
Metabolic Liver Disease Peter Eichenseer, MD No relationships to disclose. Outline Overview Alpha-1 antitrypsin deficiency Wilson s disease Hereditary hemochromatosis Pathophysiology Clinical features
More informationClinical Commissioning Policy Proposition: Treatment of iron overload for transfused and non transfused patients with chronic inherited anaemias
Clinical Commissioning Policy Proposition: Treatment of iron overload for transfused and non transfused patients with chronic inherited anaemias Reference: NHS England F05X02 First published: Month Year
More informationHaemoglobinophaties EBMT 2011 Data Manager session
Haemoglobinophaties EBMT 2011 Data Manager session Presentation plan Biological characteristics Clinical characteristics Transplant resuts What is different From transplant in malignancies Between Thalassemia
More informationGeneral insights and current management of Thalassemia Intermedia. Maria Domenica Cappellini
Palermo 16 Settembre 217 General insights and current management of Thalassemia Intermedia Maria Domenica Cappellini Rare Disease Center Dept of Internal Medicine Fondazione IRCCS Cà Granda Policlinico
More informationTHALASSEMIA AND COMPREHENSIVE CARE
1 THALASSEMIA AND COMPREHENSIVE CARE Melanie Kirby MBBS, FRCP (C), Hospital for Sick Children, Toronto Associate Professor of Paediatrics, University of Toronto. Objectives 2 By the end of this presentation,
More informationAn overview of Thalassaemias and Complications
An overview of Thalassaemias and Complications Haemoglobin Haemoglobin is the most abundant protein in blood, and exists as three main types in normal adults: HbA ( ) - 97% HbA 2 ( ) - 2.5% HbF ( ) - 0.5%
More information1st International Working Group on Thalassemia:
1st International Working Group on Thalassemia: Effectiveness and safety of 10 different regimens for controlling iron overloading in Thalassemia Major CAMPUS OF HEMATOLOGY "Franco e Piera Cutino" A.O.R.
More informationIron overload in transfusion-dependent survivors of hemoglobin Bart s hydrops fetalis
Published Ahead of Print on January 25, 2018, as doi:10.3324/haematol.2017.178368. Copyright 2018 Ferrata Storti Foundation. Iron overload in transfusion-dependent survivors of hemoglobin Bart s hydrops
More informationUniversity College Hospital
University College Hospital Exjade treatment for iron overload North Central London Haemoglobinopathy Network jointly with Whittington Health, Royal Free London and Luton and Dunstable NHS Foundation Trust
More informationClassification of Anaemia
Classification of Anaemia Dr Roger Pool Department of Haematology NHLS & University of Pretoria MEASUREMENT OF HAEMATOCRIT The haematocrit ratio (Hct) is the proportion of blood made up of cells - mainly
More informationHereditary hemochromatosis and iron overload diseases
Journal of Gastroenterology and Hepatology (2002) 17 (Suppl.) S191 S195 QUADRENNIAL REVIEW Hereditary hemochromatosis and iron overload diseases LAWRIE W POWELL The Queensland Institute of Medical Research
More informationNon-transfusion-dependent thalassemia (NTDT) Bor-Sheng Ko, M.D. Ph.D. Meng-Yao Lu, M.D. National Taiwan University Hospital
Non-transfusion-dependent thalassemia (NTDT) Bor-Sheng Ko, M.D. Ph.D. Meng-Yao Lu, M.D. National Taiwan University Hospital Introduction Spectrum of thalassemia: Resulting from unbalanced α/β chains α-thalassemias
More informationHaemochromatosis International Taskforce. Introduction
Haemochromatosis International Taskforce. Annick Vanclooster, Barbara Butzeck, Brigitte Pineau, Desley White, Domenico Girelli, Emerência Teixeira, Ian Hiller, Graça Porto, Mayka Sanchez, Paulo Santos,
More informationAnaemia. The symptoms of anaemia are tiredness, shortness of breath and being pale. The anaemia in CDA is very variable.
Anaemia The symptoms of anaemia are tiredness, shortness of breath and being pale. The anaemia in CDA is very variable. In some patients, it is very mild and does not cause them significant symptoms. In
More informationCorporate Medical Policy Chelation Therapy
Corporate Medical Policy Chelation Therapy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: chelation_therapy 12/1995 2/2015 2/2016 2/2015 Description of Procedure or Service Chelation
More informationOpinion 22 January 2014
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 22 January 2014 EXJADE 125 mg, dispersible tablets B/28 (CIP 34009 376 951 1 4) B/84 (CIP 34009 376 952 8 2) EXJADE
More informationRed cell disorder. Dr. Ahmed Hasan
Red cell disorder Dr. Ahmed Hasan Things to be learned in this lecture Definition and clinical feature of anemia. Classification of anemia. Know some details of microcytic anemia Question of the lecture:
More informationCorporate Medical Policy Genetic Testing for Hereditary Hemochromatosis
Corporate Medical Policy Genetic Testing for Hereditary Hemochromatosis File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_hemochromatosis 5/2012 3/2018 3/2019 3/2018
More informationOutline. Case Study 5/17/2010. Treating Lower-Risk Myelodysplastic Syndrome (MDS) Tapan M. Kadia, MD Department of Leukemia MD Anderson Cancer Center
Treating Lower-Risk Myelodysplastic Syndrome (MDS) Tapan M. Kadia, MD Department of Leukemia MD Anderson Cancer Center Outline Case Study What is lower-risk MDS? Classification systems Prognosis Treatment
More informationHepatocellular carcinoma in hepatitis-negative patients with thalassemia intermedia: a closer look at the role of siderosis
CASE REPORT January-February, Vol. 12 No.1, 2013: 142-146 Hepatocellular carcinoma in hepatitis-negative patients with thalassemia intermedia: a closer look at the role of siderosis Joseph E. Maakaron,*
More informationEvidence-Based Approach to Managing Non-Transfusion-Dependent Thalassemias (NTDT)
Evidence-Based Approach to Managing Non-Transfusion-Dependent Thalassemias (NTDT) Ali T. Taher, MD, PhD, FRCP Professor of Medicine, Hematology & Oncology American University of Beirut Medical Center Beirut
More informationComparing the efficacy of Dexeroyx (Osveral) and Deferoxamine (Desferal) in reducing serum ferritin level in patients with thalassemia major
Comparing the efficacy of Dexeroyx (Osveral) and Deferoxamine (Desferal) in reducing serum ferritin level in patients with thalassemia major Ali Hajigholami (1) Hourieh Ansari (2) Saeid Honarmand (3) (1)
More informationExjade q (deferasirox): Important information for patients about your treatment and possible side effects
Exjade q (deferasirox): Important information for patients about your treatment and possible side effects NAME DATE Please keep this document safe for future reference. This booklet is only intended for
More informationIntroduction ORIGINAL ARTICLE
ORIGINAL ARTICLE Downloaded from ijbc.ir at 8:25 +0430 on Saturday September 1st 2018 IJBC 2010;1: 1-5 A Glance at the Cost of Chelation Therapy with Desferal and Exjade in Iran Hadipour Dehshsal M 1 *,
More informationContents SECTION 1: PHYSIOLOGY OF BLOOD
Contents SECTION 1: PHYSIOLOGY OF BLOOD Chapter 1: Overview of Physiology of Blood 1 Normal Haematopoiesis 1 Red Blood Cells 6 White Blood Cells 15 Immune System 27 Megakaryopoiesis 32 Normal Haemostasis
More informationYEAR III Pharm.D Dr. V. Chitra
YEAR III Pharm.D Dr. V. Chitra Anemia can be defined as a reduction in the hemoglobin,hematocrit or red cell number. In physiologic terms an anemia is any disorder in which the patient suffers from tissue
More informationCorporate Medical Policy
Corporate Medical Policy Chelation Therapy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: chelation_therapy 12/1995 2/2017 2/2018 2/2017 Description of Procedure or Service Chelation
More informationPractical Aspects of Iron Chelation Therapy in HSCT. Uwe Platzbecker Medical Clinic and Polyclinic I University hospital Dresden Germany
Practical Aspects of Iron Chelation Therapy in HSCT Uwe Platzbecker Medical Clinic and Polyclinic I University hospital Dresden Germany When and how to start with iron depletion? When to start with iron
More informationIron Chelation therapy in Thalassaemia Patients journey
Iron Chelation therapy in Thalassaemia Patients journey George Constantinou 11 th Annual sickle cell disease and Thalassaemia conference (ASCAT)2017 George Constantinou ASCAT 2017 1 Thalassaemia Major
More informationCLINICAL UPDATE Haemochromatosis 3rd Edition 2007 Digestive Health Foundation 2007
CLINICAL UPDATE Haemochromatosis 3rd Edition 2007 Digestive Health Foundation 2007 Table of Contents 2 Definition Iron Studies Genetics of Hereditary Haemochromatosis 4 Clinical Manifestations Diagnosis
More informationFerriScan provides an accurate assessment of body iron stores
FerriScan provides an accurate assessment of body iron stores A clinician s guide to managing transfusional iron overload with FerriScan Transfusional iron overload Patients receiving multiple blood transfusions
More informationMorbidities in Non-Transfusion-Dependent Thalassemias (NTDT)
Morbidities in Non-Transfusion-Dependent Thalassemias (NTDT) Thalassemia Intermedia: is disease morbidity as we know it today less severe than Thalassemia Major? Ali T. Taher, MD, PhD, FRCP Professor of
More informationNon-transfusion-dependent thalassemia (NTDT) Bor-Sheng Ko, M.D. Ph.D. Meng-Yao Lu, M.D. National Taiwan University Hospital
Non-transfusion-dependent thalassemia (NTDT) Bor-Sheng Ko, M.D. Ph.D. Meng-Yao Lu, M.D. National Taiwan University Hospital Introduction Transfusion dependency in thalassemia Transfusions seldom required
More informationPharmacy Coverage Guidelines are subject to change as new information becomes available.
JADENU Sprinkle (deferasirox) granules for oral use Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan.
More informationManaging peri-operative anaemiathe Papworth way. Dr Andrew A Klein Royal Papworth Hospital Cambridge UK
Managing peri-operative anaemiathe Papworth way Dr Andrew A Klein Royal Papworth Hospital Cambridge UK Conflicts of interest: Unrestricted educational grants/honoraria from CSL Behring, Brightwake Ltd,
More informationDairion Gatot, Soegiarto Ganie, Savita Handayani. Divisi Hematologi & Onkologi Medik Departemen Ilmu Penyakit Dalam FK-USU/RS H.Adam Malik Medan 2009
HAEMOLYTIC ANAEMIA Dairion Gatot, Soegiarto Ganie, Savita Handayani. Divisi Hematologi & Onkologi Medik Departemen Ilmu Penyakit Dalam FK-USU/RS H.Adam Malik Medan 2009 WHEN BY THEN Hb 9 g% transfusion
More informationBenign Disorders. Loree Larratt, MD University of Alberta
Benign Disorders Loree Larratt, MD University of Alberta Disclosures Ad boards, honorarium: Alexion, Novartis, Lundbeck, Roche Agenda Iron Overload CARE Iron Chelation Needs Assessment Program Update Myeloproliferative
More informationTherapie mit Eisenchelatoren bei chronischen Anämien
1 Therapie mit Eisenchelatoren bei chronischen Anämien 1) Tanno T, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nature Medicine 2007;13:1096-101.
More informationMEDICAL POLICY SUBJECT: CHELATION THERAPY. POLICY NUMBER: CATEGORY: Technology Assessment
MEDICAL POLICY SUBJECT: CHELATION THERAPY PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including an
More informationSee 17 for PATIENT COUNSELING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use JADENU safely and effectively. See full prescribing information for JADENU. JADENU (deferasirox)
More informationEDUCATE. MOTIVATE. CHELATE.
EDUCATE. MOTIVATE. CHELATE. Guiding patients through treatment with JADENU (deferasirox) tablets IMPORTANT SAFETY INFORMATION for JADENU WARNING: RENAL FAILURE, HEPATIC FAILURE, AND GASTROINTESTINAL HEMORRHAGE
More informationIn adults, the predominant Hb (HbA) molecule has four chains: two α and two β chains. In thalassemias, the synthesis of either the α or the β chains
Thalassaemias Thalassemia Thalassemia is an inherited autosomal recessive blood disease. Associated with absence or reduction in a or b globin chains. Reduced synthesis of one of the globin chains can
More informationINDICATIONS Treatment of Chronic Iron Overload Due to Blood Transfusions (Transfusional Iron Overload) EXJADE (deferasirox) is indicated for the
INDICATIONS Treatment of Chronic Iron Overload Due to Blood Transfusions (Transfusional Iron Overload) EXJADE (deferasirox) is indicated for the treatment of chronically elevated levels of iron in the
More informationDependance on chronic transfusion
Dependance on chronic transfusion Pr Saliou Diop Hematology Blood transfusion Dakar- Sénégal diop@cnts-dakar.sn Introduction Chronic transfusion: Regular use of blood transfusion in patients with chronic
More informationSickle Cell Anemia and ß-Thalassemia
Sickle Cell Anemia and ß-Thalassemia Adult Hemoglobin Heme Mutations that alter the structure (Glutamic acid to Valine at position 6) Mutations that reduce the synthesis Heme Sickling Hb and red cells
More informationIntroduction 5/2/2013 IRON RELATED GENES AND OXIDATIVE STRESS IN NON- ALCOHOLIC STEATOHEPATITIS. Iron Physiology. Iron Physiology
// IRON RELATED GENES AND OXIDATIVE STRESS IN NON- ALCOHOLIC STEATOHEPATITIS DIANA MOYA, MD PEDIATRIC GASTROENTEROLOGY FELLOW DIGESTIVE DISEASES & NUTRITION CENTER MAY,. Iron Physiology. /NAFLD. Iron Metabolism
More information2011 ASH Annual Meeting Targeting the Hepcidin Pathway with RNAi Therapeutics for the Treatment of Anemia. December 12, 2011
211 ASH Annual Meeting Targeting the Hepcidin Pathway with RNAi Therapeutics for the Treatment of Anemia December 12, 211 Hepcidin is Central Regulator of Iron Homeostasis Hepcidin is liver-expressed,
More informationΧριστίνα Χρυσοχόου Α Καρδιολογική Κλινική Πανεπιστηίου Αθηνών
Ιωάννης Ανδρέου Χριστίνα Χρυσοχόου Α Καρδιολογική Κλινική Πανεπιστηίου Αθηνών Ιπποκράτειο Γ.Ν.Α Splenectomy at the age of 7yrs Episodes of persistent atrial fibrillation Hypothyroidism Osteoporosis Noncompliant
More informationMetabolic Liver Disease: What s New in Diagnosis and Therapy?
Metabolic Liver Disease: What s New in Diagnosis and Therapy? Bruce R. Bacon, M.D. James F. King M.D. Endowed Chair in Gastroenterology Professor of Internal Medicine Division of Gastroenterology and Hepatology
More information